BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

586 related articles for article (PubMed ID: 25877817)

  • 1. MicroRNAs in diabetic nephropathy: functions, biomarkers, and therapeutic targets.
    Kato M; Natarajan R
    Ann N Y Acad Sci; 2015 Sep; 1353(1):72-88. PubMed ID: 25877817
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Circular RNAs; powerful microRNA sponges to overcome diabetic nephropathy.
    Mafi A; Yadegar N; Salami M; Salami R; Vakili O; Aghadavod E
    Pathol Res Pract; 2021 Nov; 227():153618. PubMed ID: 34649056
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diabetic nephropathy--emerging epigenetic mechanisms.
    Kato M; Natarajan R
    Nat Rev Nephrol; 2014 Sep; 10(9):517-30. PubMed ID: 25003613
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MicroRNAs in Diabetic Nephropathy: From Biomarkers to Therapy.
    Simpson K; Wonnacott A; Fraser DJ; Bowen T
    Curr Diab Rep; 2016 Mar; 16(3):35. PubMed ID: 26973290
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MicroRNAs and the glomerulus.
    Kato M; Park JT; Natarajan R
    Exp Cell Res; 2012 May; 318(9):993-1000. PubMed ID: 22421514
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effects of expression of different microRNAs on insulin secretion and diabetic nephropathy progression.
    Mafi A; Aghadavod E; Mirhosseini N; Mobini M; Asemi Z
    J Cell Physiol; 2018 Jan; 234(1):42-50. PubMed ID: 30078212
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MicroRNA: A new generation therapeutic target in diabetic nephropathy.
    Dewanjee S; Bhattacharjee N
    Biochem Pharmacol; 2018 Sep; 155():32-47. PubMed ID: 29940170
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MicroRNAs in diabetic nephropathy: From molecular mechanisms to new therapeutic targets of treatment.
    Yarahmadi A; Shahrokhi SZ; Mostafavi-Pour Z; Azarpira N
    Biochem Pharmacol; 2021 Jul; 189():114301. PubMed ID: 33203517
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of novel targets of diabetic nephropathy and PEDF peptide treatment using RNA-seq.
    Rubin A; Salzberg AC; Imamura Y; Grivitishvilli A; Tombran-Tink J
    BMC Genomics; 2016 Nov; 17(1):936. PubMed ID: 27855634
    [TBL] [Abstract][Full Text] [Related]  

  • 10. RNA expression signatures and posttranscriptional regulation in diabetic nephropathy.
    Rudnicki M; Beckers A; Neuwirt H; Vandesompele J
    Nephrol Dial Transplant; 2015 Aug; 30 Suppl 4():iv35-42. PubMed ID: 26209736
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MicroRNA circuits in transforming growth factor-β actions and diabetic nephropathy.
    Kato M; Natarajan R
    Semin Nephrol; 2012 May; 32(3):253-60. PubMed ID: 22835456
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ski-related novel protein suppresses the development of diabetic nephropathy by modulating transforming growth factor-β signaling and microRNA-21 expression.
    Wang Y; Liu L; Peng W; Liu H; Liang L; Zhang X; Mao Y; Zhou X; Shi M; Xiao Y; Zhang F; Zhang Y; Liu L; Yan R; Guo B
    J Cell Physiol; 2019 Aug; 234(10):17925-17936. PubMed ID: 30847937
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emerging roles for miRNAs in the development, diagnosis, and treatment of diabetic nephropathy.
    DiStefano JK; Taila M; Alvarez ML
    Curr Diab Rep; 2013 Aug; 13(4):582-91. PubMed ID: 23666892
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Noncoding RNAs in Diabetic Nephropathy: Pathogenesis, Biomarkers, and Therapy.
    Lv J; Wu Y; Mai Y; Bu S
    J Diabetes Res; 2020; 2020():3960857. PubMed ID: 32656264
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transforming growth factor β1 (TGF-β1) enhances expression of profibrotic genes through a novel signaling cascade and microRNAs in renal mesangial cells.
    Castro NE; Kato M; Park JT; Natarajan R
    J Biol Chem; 2014 Oct; 289(42):29001-13. PubMed ID: 25204661
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bioinformatics Analysis of the Mechanisms of Diabetic Nephropathy
    Guo M; Dai Y; Jiang L; Gao J
    Front Endocrinol (Lausanne); 2022; 13():934022. PubMed ID: 35909518
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stem cell-derived and circulating exosomal microRNAs as new potential tools for diabetic nephropathy management.
    Peng L; Chen Y; Shi S; Wen H
    Stem Cell Res Ther; 2022 Jan; 13(1):25. PubMed ID: 35073973
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Urine miRNAs: potential biomarkers for monitoring progression of early stages of diabetic nephropathy.
    Yang Y; Xiao L; Li J; Kanwar YS; Liu F; Sun L
    Med Hypotheses; 2013 Aug; 81(2):274-8. PubMed ID: 23683774
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Circular RNAs: An emerging precise weapon for diabetic nephropathy diagnosis and therapy.
    Shu H; Zhang Z; Liu J; Chen P; Yang C; Wu Y; Wu D; Cao Y; Chu Y; Li L
    Biomed Pharmacother; 2023 Dec; 168():115818. PubMed ID: 37939612
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Repression of let-7 by transforming growth factor-β1-induced Lin28 upregulates collagen expression in glomerular mesangial cells under diabetic conditions.
    Park JT; Kato M; Lanting L; Castro N; Nam BY; Wang M; Kang SW; Natarajan R
    Am J Physiol Renal Physiol; 2014 Dec; 307(12):F1390-403. PubMed ID: 25354942
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.